News Releases

Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

FOSTER CITY, Calif. --(BUSINESS WIRE)--Aug. 7, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz , president and chief executive officer

Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates

Rolling NDA submission for maralixibat in Alagille syndrome (ALGS) to be initiated in third quarter 2020; planning for potential launch in second half of 2021. Submission of European marketing authorization application for maralixibat in PFIC2 planned for fourth quarter of 2020.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jul. 10, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that the Compensation

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 11, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that the Compensation

Mirum’s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis

- Maralixibat-treated patients achieving serum bile acid control have five-year native liver survival after treatment. - Data demonstrate normalization and reductions of liver enzymes, reduced pruritus, and improved growth. - Data selected for oral presentation at the Digital International Liver

Mirum Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference

FOSTER CITY, Calif. --(BUSINESS WIRE)--May 29, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz , president and chief executive officer

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. --(BUSINESS WIRE)--May 11, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that the Compensation Committee

Mirum Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Updates

- On track to begin rolling submission of NDA for maralixibat in Alagille Syndrome (ALGS) in third quarter 2020 - Cash, cash equivalents and investments balance of $166.1 million FOSTER CITY, Calif. --(BUSINESS WIRE)--May 7, 2020-- Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer

FOSTER CITY, Calif. --(BUSINESS WIRE)--Apr. 28, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced the appointment of Peter

Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

New Drug Application Rolling Submission for Alagille Syndrome Planned to Begin in Third Quarter 2020 Cash, Cash Equivalents and Investments Balance of $140.0 million before gross proceeds of $48.0 million from a follow-on public offering in January 2020 On Track for PFIC Phase 3 Top-Line Data and

News Releases

News Releases

Header Menu